Why the study?
Does renal artery denervation reduce systolic blood pressure in patients with resistant hypertension?
Does renal artery denervation reduce systolic blood pressure in patients with resistant hypertension?
Answers are grounded in this paper and cite their sources.
The review explores potential basic and clinical factors that may explain the failure of the Symplicity-3HTN trial to show efficacy for renal artery denervation in resistant hypertension.
Symplicity-3 hypertension (HTN) was a recently completed clinical trial that was assumed to be the basis for the approved use of renal artery denervation for the treatment of resistant hypertension in the United States. Dramatic reductions in blood pressure had been reported in two clinical trials (Symplicity-1HTN, -2HTN) carried out in Europe, however Symplicity-3HTN did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 mo after renal artery denervation as compared with a sham control. (Denervation group, blood pressure reduction: -14 ± 24, Sham control: -12 ± 26 mmHg). In this review we discuss several potential explanations for the failure of efficacy of Symplicity-3HTN taking into account basic and clinical factors which could have played a role in the discrepancy between the European and American experience.
No takes yet. Share an insight, caveat, or question.
Benjamin J. Scherlag (2015) conducted a review in resistant hypertension. renal artery denervation vs. sham control was evaluated on reduction of systolic blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: